Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Alk-Abello Gains Most in 16 Months on Dust Mite Deal

ALK-Abello A/S, the world’s largest maker of immunotherapy treatments, gained the most in 16 months in Copenhagen trading after agreeing to license its anti-dust mite allergy drugs in a transaction worth potentially more than 60 million euros ($82 million).

ALK gained 10 percent after the Hoersholm, Denmark-based drugmaker agreed to license its products in Japan to Torii Pharmaceutical Co. Torii will pay ALK 30 million euros up front, another 30 million euros in milestone payments, and royalties.

The Danish company aims to broaden the market for its allergy treatments by converting them from injections taken over the course of several years, into tablets. Under the agreement, Toyko-based Torii gains rights to develop and sell ALK’s dust mite pill Mitizax, market its injection version and develop a cedar pollen allergy pill.

ALK advanced 33 kroner to 353.50 kroner, giving it a market value of 3.58 billion kroner ($654 million.) The stock has fallen 14 percent in the past 12 months, compared with a 2.7 percent gain in the Bloomberg Europe Pharmaceutical Index.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.